vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and HIVE Digital Technologies Ltd. (HIVE). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $93.1M, roughly 1.5× HIVE Digital Technologies Ltd.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -98.1%, a 133.6% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 18.4%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
ADMA vs HIVE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $93.1M |
| Net Profit | $49.4M | $-91.3M |
| Gross Margin | 63.8% | -27.1% |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | -98.1% |
| Revenue YoY | 18.4% | 218.6% |
| Net Profit YoY | -55.9% | -234.0% |
| EPS (diluted) | $0.20 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $93.1M | ||
| Q3 25 | $134.2M | $87.3M | ||
| Q2 25 | $122.0M | $45.6M | ||
| Q1 25 | $114.8M | — | ||
| Q4 24 | $117.5M | $29.2M | ||
| Q3 24 | $119.8M | $22.6M | ||
| Q2 24 | $107.2M | $32.2M | ||
| Q1 24 | $81.9M | — |
| Q4 25 | $49.4M | $-91.3M | ||
| Q3 25 | $36.4M | $-15.8M | ||
| Q2 25 | $34.2M | $35.0M | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $111.9M | $68.2M | ||
| Q3 24 | $35.9M | $80.0K | ||
| Q2 24 | $32.1M | $-18.3M | ||
| Q1 24 | $17.8M | — |
| Q4 25 | 63.8% | -27.1% | ||
| Q3 25 | 56.3% | 4.7% | ||
| Q2 25 | 55.1% | -13.6% | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | -43.7% | ||
| Q3 24 | 49.8% | -66.1% | ||
| Q2 24 | 53.6% | -7.4% | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | -98.1% | ||
| Q3 25 | 27.1% | -18.1% | ||
| Q2 25 | 28.1% | 76.8% | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 95.2% | 233.2% | ||
| Q3 24 | 30.0% | 0.4% | ||
| Q2 24 | 29.9% | -56.7% | ||
| Q1 24 | 21.7% | — |
| Q4 25 | $0.20 | $-0.38 | ||
| Q3 25 | $0.15 | $-0.07 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | $0.52 | ||
| Q3 24 | $0.15 | $0.00 | ||
| Q2 24 | $0.13 | $-0.17 | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $559.3M |
| Total Assets | $624.2M | $624.0M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | $40.5M | ||
| Q3 24 | $86.7M | $31.7M | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $559.3M | ||
| Q3 25 | $431.2M | $624.6M | ||
| Q2 25 | $398.3M | $560.5M | ||
| Q1 25 | $373.4M | — | ||
| Q4 24 | $349.0M | $430.9M | ||
| Q3 24 | $231.9M | $275.5M | ||
| Q2 24 | $188.3M | $268.6M | ||
| Q1 24 | $153.7M | — |
| Q4 25 | $624.2M | $624.0M | ||
| Q3 25 | $568.7M | $693.0M | ||
| Q2 25 | $558.4M | $628.7M | ||
| Q1 25 | $510.6M | — | ||
| Q4 24 | $488.7M | $478.6M | ||
| Q3 24 | $390.6M | $334.7M | ||
| Q2 24 | $376.4M | — | ||
| Q1 24 | $350.9M | — |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $46.0M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $46.0M | ||
| Q3 25 | $13.3M | $-10.6M | ||
| Q2 25 | $21.1M | $10.2M | ||
| Q1 25 | $-19.7M | — | ||
| Q4 24 | $50.2M | $-28.5M | ||
| Q3 24 | $25.0M | $-2.2M | ||
| Q2 24 | $45.6M | $-4.4M | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $-55.5M | ||
| Q3 24 | $24.0M | $-34.7M | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | -189.9% | ||
| Q3 24 | 20.0% | -153.4% | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | 92.5% | ||
| Q3 24 | 0.9% | 143.9% | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 0.29× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | -0.42× | ||
| Q3 24 | 0.70× | -26.94× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
HIVE
Segment breakdown not available.
